[ad_1]
Jakarta, CNBC Indonesia – Sinovac Biotech Ltd., a company that produces China’s corona virus (Covid-19) vaccine. talk about the effectiveness of your vaccine. The clarification came after Sinovac’s partner in Indonesia, one of the top officials at PT Bio Farma, said that the vaccine had been shown to be 97% effective in clinical trials in Indonesia, although it was eventually clarified. Read here.
A Sinovac spokesman said Tuesday that the 97% figure refers to the seroconversion rate, which is independent of the vaccine’s efficacy. However, a high seroconversion rate does not necessarily mean that the vaccine effectively protects people from Covid-19.
The Beijing-based company and its partners are still analyzing data from the phase III trial in Brazil, where they hope to get an indication of how effective the vaccine is based on about 60 cases of Covid-19, a Sinovac spokesperson said. The results of the tests in Brazil are scheduled to be announced on December 15, 2020.
PT Bio Farma also briefly clarified the effectiveness of the Sinovac vaccine, which was initially said to have reached 97%. Bio Farma Corporate Secretary Bambang Heriyanto said the interim report on the results of the clinical trial is expected to be published in January 2021.
“As of now, the phase 3 clinical trial is still ongoing, and the interim report is estimated to be available in January,” Bambang told CNBC Indonesia on Tuesday.
Bambang said the report from the Padjadjaran University School of Medicine clinical trial team would become a reference for the Food and Drug Supervision Agency (BPOM) to grant permission for its emergency use.
“Clinical trial data from the Unpad College of Medicine clinical trial team will then be sent directly to BPOM for evaluation for the approval process for emergency use,” he explained.
Unlike Western vaccine pioneers, none of China’s leading vaccine developers have published data on the efficacy of their injections in phase III trials, making it difficult to compare their vaccines or estimate how quickly they might receive approval. for general use.
However, the doses have been administered to hundreds of thousands of local people under China’s emergency use program. This has raised concerns among scientists about the potential risks of using a vaccine whose safety has not been thoroughly studied.
Pfizer Inc. in November said that the vaccine developed jointly with BioNTech SE had a protection rate of more than 90%. This high level of efficacy was also seen in a photo from Moderna Inc., which uses similar mRNA technology.
Preliminary data from the analysts also showed that a vaccine made by AstraZeneca Plc, a viral vector developed with the University of Oxford, prevented an average of 70% of the participants from getting sick.
The Sinovac vaccine is based on an inactivated version of the new coronavirus to teach the human immune system to recognize and destroy the real one. It is a widely used method in vaccines against many other diseases such as hepatitis, flu, and polio.
While the extraordinary figures published by the experimental mRNA vaccines will be difficult to replicate. Drug regulators and the World Health Organization (WHO) also continue to consider a viable vaccine if it can protect at least 50% of people from contracting Covid-19.
According to Worldometers data, corona cases in the world now exceed 68.7 million positive people, with 1.5 million deaths and 47.6 million patients have recovered.
[Gambas:Video CNBC]
(Hello Hello)
